Palatin Technologies Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Carl Spana

Geschäftsführender

US$1.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	53.7%
Amtszeit als Geschäftsführer	24yrs
Eigentum des Geschäftsführers	0.6%
Durchschnittliche Amtszeit des Managements	13.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	18.9yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Carl Spana im Vergleich zu den Einnahmen von Palatin Technologies verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$35m
Dec 31 2023	n/a	n/a	-US$35m
Sep 30 2023	n/a	n/a	-US$25m
Jun 30 2023	US$1m	US$700k	-US$28m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	n/a	n/a	-US$26m
Sep 30 2022	n/a	n/a	-US$37m
Jun 30 2022	US$1m	US$640k	-US$36m
Mar 31 2022	n/a	n/a	-US$37m
Dec 31 2021	n/a	n/a	-US$35m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	US$2m	US$620k	-US$34m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	n/a	n/a	-US$27m
Sep 30 2020	n/a	n/a	-US$22m
Jun 30 2020	US$2m	US$600k	-US$22m
Mar 31 2020	n/a	n/a	US$37m
Dec 31 2019	n/a	n/a	US$37m
Sep 30 2019	n/a	n/a	US$37m
Jun 30 2019	US$2m	US$505k	US$36m
Mar 31 2019	n/a	n/a	-US$5m
Dec 31 2018	n/a	n/a	US$344k
Sep 30 2018	n/a	n/a	US$8m
Jun 30 2018	US$3m	US$491k	US$25m
Mar 31 2018	n/a	n/a	US$26m
Dec 31 2017	n/a	n/a	US$23m
Sep 30 2017	n/a	n/a	US$10m
Jun 30 2017	US$2m	US$476k	-US$13m

Vergütung im Vergleich zum Markt: CarlDie Gesamtvergütung ($USD1.30M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt German ($USD434.45K).

Entschädigung vs. Einkommen: CarlDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Carl Spana (62 yo)

24yrs

Amtszeit

US$1,303,800

Vergütung

Dr. Carl Spana, Ph D., is a Co-Founder of Palatin Technologies Inc and has been its Chief Executive Officer and President since June 14, 2000. From June 1996 to June 14, 2000, Dr. Spana served as an Chief...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Carl Spana	Co-Founder	24yrs	US$1.30m	0.60% $ 172.3k
Stephen Wills	CFO, COO	26.6yrs	US$1.19m	0.56% $ 161.0k
Burns McClellan	Vice President of Investor Relations	no data	keine Daten	keine Daten
Stephen Slusher	Chief Legal Officer	no data	keine Daten	keine Daten
Michael Raizman	Chief Medical Officer	3yrs	keine Daten	keine Daten
James Hattersley	Senior Vice President of Business Development	3yrs	keine Daten	keine Daten
John Dodd	Senior Vice President of Preclinical Development	no data	keine Daten	keine Daten
Robert Jordan	Senior Vice President of Program Operations	no data	keine Daten	keine Daten

13.5yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrenes Management: PTNDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (13.5 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Carl Spana	Co-Founder	28yrs	US$1.30m	0.60% $ 172.3k
John K. Prendergast	Independent Non-Executive Chairman	27.8yrs	US$154.88k	0.17% $ 49.3k
Arlene Morris	Independent Director	9yrs	US$97.47k	0.11% $ 31.1k
Robert deVeer	Independent Director	25.6yrs	US$112.47k	0.080% $ 22.7k
Alan Dunton	Independent Director	13yrs	US$112.47k	0.11% $ 30.9k
Anthony Manning	Independent Director	6.8yrs	US$97.47k	0.084% $ 23.8k
Raymond Rosen	Member of Female Sexual Dysfunction Expert Panel	no data	keine Daten	keine Daten
Michael Perelman	Member of Female Sexual Dysfunction Expert Panel	19.1yrs	keine Daten	keine Daten
J. Hull	Independent Director	18.8yrs	US$102.47k	0.11% $ 30.2k
Anita Clayton	Member of Female Sexual Dysfunction Expert Panel	no data	keine Daten	keine Daten
Leonard Derogatis	Member of Female Sexual Dysfunction Expert Panel	no data	keine Daten	keine Daten
Stanley Althof	Member of Female Sexual Dysfunction Expert Panel	no data	keine Daten	keine Daten

18.9yrs

Durchschnittliche Betriebszugehörigkeit

70yo

Durchschnittliches Alter

Erfahrener Vorstand: PTNDie Vorstandsmitglieder sind sehr erfahren ( 18.9 ).

Palatin Technologies Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Palatin Technologies, Inc., Annual General Meeting, Jun 27, 2024

Palatin Technologies, Inc., Annual General Meeting, Jun 20, 2023

Insufficient new directors

Palatin Technologies, Inc. Announces Appointment of Carl Spana as Chief Executive Officer Effective July 1, 2022

Palatin Technologies, Inc., Annual General Meeting, Jun 24, 2022

Insufficient new directors

Recent updates

Palatin Technologies, Inc. Announces Initiation of Phase 2 Clinical Study of Bremelanotide Co-Administered with PDE5i for Treatment of Erectile Dysfunction

Palatin Technologies, Inc. Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

Palatin Technologies, Inc., Annual General Meeting, Jun 27, 2024

Third quarter 2024 earnings released: US$0.53 loss per share (vs US$0.63 loss in 3Q 2023)

Palatin Technologies, Inc. to Report Q3, 2024 Results on May 15, 2024

Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease (Ded) Clinical Data Results Presented At American Society of Cataract and Refractive Surgery (Ascrs) 2024

No longer forecast to breakeven

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.13 loss in 2Q 2023)

Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

New major risk - Shareholder dilution

Palatin Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $10.000006 million.

Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024

Forecast to breakeven in 2026

Palatin Technologies Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.86 loss in 1Q 2023)

Palatin Technologies, Inc. to Report Q1, 2024 Results on Nov 14, 2023

Palatin Technologies, Inc. announced that it expects to receive $5.000001 million in funding

Palatin Technoloes, Inc. Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

Palatin Receives Notice of Non-Compliance from NYSE American

Palatin Receives Notice of Non-Compliance from NYSE American

Full year 2023 earnings released: US$2.53 loss per share (vs US$3.79 loss in FY 2022)

Palatin Technologies, Inc. to Report Q4, 2023 Results on Sep 28, 2023

Palatin Technologies, Inc. Completes Enrollment in Phase 3 Melody-1 Study of PL9643 for the Treatment of Patients with Dry Eye Disease

Palatin Technologies, Inc. Initiates Clinical Program for Bremelanotide Co-Formulated with A Pde5i for the Treatment of Ed in Patients Non-Responsive to Pde5i Treatment

Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

New major risk - Share price stability

Palatin Technologies, Inc., Annual General Meeting, Jun 20, 2023

Third quarter 2023 earnings released: US$0.63 loss per share (vs US$0.80 loss in 3Q 2022)

Palatin Technologies, Inc. to Report Q3, 2023 Results on May 16, 2023

Palatin Technologies, Inc. Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.91 loss in 2Q 2022)

Palatin Technologies, Inc. to Report Q2, 2023 Results on Feb 15, 2023

Palatin Technologies Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions

Forecast to breakeven in 2025

Insufficient new directors

Palatin Technologies, Inc. to Report Q1, 2023 Results on Nov 14, 2022

Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $9.999921 million.

Palatin Technologies, Inc. Announces First Patient Has Been Enrolled in the Pl8177-205 Study with Palatin's Pl8177

Full year 2022 earnings released: US$3.79 loss per share (vs US$3.55 loss in FY 2021)

Palatin Technologies, Inc. to Report Q4, 2022 Results on Sep 22, 2022

Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis

Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease

Palatin Technologies, Inc. Announces Appointment of Carl Spana as Chief Executive Officer Effective July 1, 2022

Palatin Technologies, Inc., Annual General Meeting, Jun 24, 2022

Third quarter 2022 earnings released: US$0.032 loss per share (vs US$0.024 loss in 3Q 2021)

Palatin Technologies, Inc. to Report Q3, 2022 Results on May 17, 2022

Insufficient new directors

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Palatin Technologies, Inc. to Report Q2, 2022 Results on Feb 15, 2022

Palatin Technologies, Inc. Announces Initiation of Pivotal Phase 3 Pl9643 Melody-1 Clinical Trial in Patients with Dry Eye Disease

First quarter 2022 earnings released: US$0.03 loss per share (vs US$0.017 loss in 1Q 2021)

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.096 loss in FY 2020)

Palatin Technologies, Inc. Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting

Palatin Technologies, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease

Palatin Technologies, Inc. Announces U.S. Patent Term Extension for Vyleesi

Revenue misses expectations

Palatin Technologies, Inc. to Report Q2, 2021 Results on Feb 17, 2021

New 90-day high: €1.02

Palatin Technologies Announces Filing of International Patent Application Claiming PL9643

New 90-day high: €0.65

New 90-day high: €0.47

Angela Rossetti, an Independent Director, Resigned from the Board of Directors of Palatin Technologies, Inc. and as A Member of the Company’s Audit Committee and Nominating and Corporate Governance Committee

Palatin Technologies Announces Positive Results From its Phase 2 Study of PL9643 in Patients With Dry Eye Disease

Revenue misses expectations

Palatin Technologies, Inc. to Report Q1, 2021 Results on Nov 17, 2020

New 90-day low: €0.38

New 90-day low: €0.40

Palatin Technologies, Inc. to Report Q4, 2020 Results on Sep 28, 2020